Letermovir (Prevymis) was shown to be non-inferior to valganciclovir (Valcyte), the standard of care, in a clinical trial of cytomegalovirus (CMV) prophylaxis in high-risk kidney transplant patients, the researchers reported. In a phase III study of 589 patients randomized 1:1 to receive both drugs up to 200 days post-transplant, the 1-year prevalence of CMV disease was not significantly different in the letermovir group compared to the valganciclovir group (10.4 % vs 11.8%, adjusted difference -1.4%, 95% CI -6.5% to 3.8%), reported Ajit Limaye, MD, of the University of Washington Medicine…
Read More